(Alliance News) - PureTech Health PLC said Monday its founded entity Vor Biopharma has filed for an initial public offering with the US Securities & Exchange Commission to list on the Nasdaq Global Market.
"The number of shares to be offered and the price range for the offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering," PureTech added.
Goldman Sachs & Co LLC is the lead book runner for the proposed offering.
Last week, Vor Biopharma, a clinical-stage cell therapy company making engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer, said the US Food & Drug Administration cleared the company's investigational new drug application for VOR33, an eHSC therapy candidate being developed for the treatment of acute myeloid leukemia.
Vor plans to initiate a Phase 1/2a clinical trial for VOR33 in the first half of this year.
Shares in PureTech Health were 0.8% higher at 384.44 pence each in London on Monday.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)